Synairgen plc Extension of clinical study in COVID-19 patients (5139L)
April 30 2020 - 7:09AM
UK Regulatory
TIDMSNG
RNS Number : 5139L
Synairgen plc
30 April 2020
Press release
Synairgen plc
('Synairgen' or the 'Company')
Approval received to extend SG016 clinical study of SNG001 in
COVID-19 to initiate patients in the home environment
Southampton, UK - 30 April 2020: Synairgen plc (LSE: SNG), the
respiratory drug discovery and development company, announces that
it has received approvals to extend the SG016 trial to patients
with SARS-CoV-2 in the home environment. The objective is to
initiate dosing with SNG001 (or placebo) earlier in the infection
cycle, and before severe lower respiratory tract symptoms have
developed. In due course, details of the design, implementation and
timing of this novel study will be disclosed more fully.
The treatment of patients in the hospital setting in the SG016
study is progressing well, with more than 75 patients out of the
target 100 now dosed with Synairgen's wholly-owned drug SNG001 or
placebo. Results from this part of the study are still expected in
June 2020.
For further enquiries, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Finance Director
Tel: + 44 (0) 23 8051 2800
finnCap
Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate
Finance)
Alice Lane, Manasa Patil (ECM)
Tel: + 44 (0) 20 7220 0500
Consilium Strategic Communications (Financial Media and
Investor
Relations)
Mary-Jane Elliott, Sue Stuart, Olivia Manser
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
Notes for Editors
About Synairgen
Synairgen is a respiratory drug discovery and development
company founded by University of Southampton Professors Stephen
Holgate, Donna Davies and Ratko Djukanovic. The business, focused
primarily on lung viral defence in asthma and COPD, uses its
differentiating human biology BioBank platform and world-renowned
international academic KOL network to discover and develop novel
therapies for respiratory disease.
Synairgen is quoted on AIM (LSE: SNG). For more information
about Synairgen, please see www.synairgen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCURRARRSUSOAR
(END) Dow Jones Newswires
April 30, 2020 07:09 ET (11:09 GMT)
Synairgen (LSE:SNG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Synairgen (LSE:SNG)
Historical Stock Chart
From Apr 2023 to Apr 2024
